Adenocarcinoma of the esophagogastric junction in Japan

Manabu Yamamoto, Hideo Baba, Akinori Egashira, Eiji Oki, Masahiko Ikebe, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: The prognosis of adenocarcinoma of the esophagogastric junction is worse than that in adenocarcinoma of other parts of the stomach. In particular, the clinical features and prognosis of adenocarcinoma of the esophagogastric junction and the differences between Siewert's type II and III tumors in Japan were evaluated. Methodology: We analyzed one hundred and forty patients with adenocarcinoma of the esophagogastric junction including one patient with a type I tumor, sixty-seven patients with type II tumors, and seventy-two patients with type III tumors. Results: The prognosis of patients with type III tumors was poorer in comparison to that of type II tumors in adenocarcinoma of the esophagogastric junction (p<0.05). A significant difference was observed in the survival of patients with type III tumors between those with positive and negative lymph nodes (p<0.001). However, there was no such difference in patients with type II tumors. In a multivariate analysis, lymph node metastasis, age and the depth of tumor invasion were all found to be independent prognostic factors. Conclusions: The prognosis of patients with lymph node metastasis of type III adenocarcinoma of the esophagogastric junction was found to be extremely poor. An aggressive treatment after surgery may therefore be necessary to improve the survival of this population.

Original languageEnglish
Pages (from-to)103-107
Number of pages5
JournalHepato-Gastroenterology
Volume55
Issue number81
Publication statusPublished - Jan 1 2008

Fingerprint

Esophagogastric Junction
Japan
Adenocarcinoma
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Survival
Stomach
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Yamamoto, M., Baba, H., Egashira, A., Oki, E., Ikebe, M., Kakeji, Y., & Maehara, Y. (2008). Adenocarcinoma of the esophagogastric junction in Japan. Hepato-Gastroenterology, 55(81), 103-107.

Adenocarcinoma of the esophagogastric junction in Japan. / Yamamoto, Manabu; Baba, Hideo; Egashira, Akinori; Oki, Eiji; Ikebe, Masahiko; Kakeji, Yoshihiro; Maehara, Yoshihiko.

In: Hepato-Gastroenterology, Vol. 55, No. 81, 01.01.2008, p. 103-107.

Research output: Contribution to journalArticle

Yamamoto, M, Baba, H, Egashira, A, Oki, E, Ikebe, M, Kakeji, Y & Maehara, Y 2008, 'Adenocarcinoma of the esophagogastric junction in Japan', Hepato-Gastroenterology, vol. 55, no. 81, pp. 103-107.
Yamamoto M, Baba H, Egashira A, Oki E, Ikebe M, Kakeji Y et al. Adenocarcinoma of the esophagogastric junction in Japan. Hepato-Gastroenterology. 2008 Jan 1;55(81):103-107.
Yamamoto, Manabu ; Baba, Hideo ; Egashira, Akinori ; Oki, Eiji ; Ikebe, Masahiko ; Kakeji, Yoshihiro ; Maehara, Yoshihiko. / Adenocarcinoma of the esophagogastric junction in Japan. In: Hepato-Gastroenterology. 2008 ; Vol. 55, No. 81. pp. 103-107.
@article{2c4db94c6b5442a0a667a8e14c491bf3,
title = "Adenocarcinoma of the esophagogastric junction in Japan",
abstract = "Background/Aims: The prognosis of adenocarcinoma of the esophagogastric junction is worse than that in adenocarcinoma of other parts of the stomach. In particular, the clinical features and prognosis of adenocarcinoma of the esophagogastric junction and the differences between Siewert's type II and III tumors in Japan were evaluated. Methodology: We analyzed one hundred and forty patients with adenocarcinoma of the esophagogastric junction including one patient with a type I tumor, sixty-seven patients with type II tumors, and seventy-two patients with type III tumors. Results: The prognosis of patients with type III tumors was poorer in comparison to that of type II tumors in adenocarcinoma of the esophagogastric junction (p<0.05). A significant difference was observed in the survival of patients with type III tumors between those with positive and negative lymph nodes (p<0.001). However, there was no such difference in patients with type II tumors. In a multivariate analysis, lymph node metastasis, age and the depth of tumor invasion were all found to be independent prognostic factors. Conclusions: The prognosis of patients with lymph node metastasis of type III adenocarcinoma of the esophagogastric junction was found to be extremely poor. An aggressive treatment after surgery may therefore be necessary to improve the survival of this population.",
author = "Manabu Yamamoto and Hideo Baba and Akinori Egashira and Eiji Oki and Masahiko Ikebe and Yoshihiro Kakeji and Yoshihiko Maehara",
year = "2008",
month = "1",
day = "1",
language = "English",
volume = "55",
pages = "103--107",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "81",

}

TY - JOUR

T1 - Adenocarcinoma of the esophagogastric junction in Japan

AU - Yamamoto, Manabu

AU - Baba, Hideo

AU - Egashira, Akinori

AU - Oki, Eiji

AU - Ikebe, Masahiko

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background/Aims: The prognosis of adenocarcinoma of the esophagogastric junction is worse than that in adenocarcinoma of other parts of the stomach. In particular, the clinical features and prognosis of adenocarcinoma of the esophagogastric junction and the differences between Siewert's type II and III tumors in Japan were evaluated. Methodology: We analyzed one hundred and forty patients with adenocarcinoma of the esophagogastric junction including one patient with a type I tumor, sixty-seven patients with type II tumors, and seventy-two patients with type III tumors. Results: The prognosis of patients with type III tumors was poorer in comparison to that of type II tumors in adenocarcinoma of the esophagogastric junction (p<0.05). A significant difference was observed in the survival of patients with type III tumors between those with positive and negative lymph nodes (p<0.001). However, there was no such difference in patients with type II tumors. In a multivariate analysis, lymph node metastasis, age and the depth of tumor invasion were all found to be independent prognostic factors. Conclusions: The prognosis of patients with lymph node metastasis of type III adenocarcinoma of the esophagogastric junction was found to be extremely poor. An aggressive treatment after surgery may therefore be necessary to improve the survival of this population.

AB - Background/Aims: The prognosis of adenocarcinoma of the esophagogastric junction is worse than that in adenocarcinoma of other parts of the stomach. In particular, the clinical features and prognosis of adenocarcinoma of the esophagogastric junction and the differences between Siewert's type II and III tumors in Japan were evaluated. Methodology: We analyzed one hundred and forty patients with adenocarcinoma of the esophagogastric junction including one patient with a type I tumor, sixty-seven patients with type II tumors, and seventy-two patients with type III tumors. Results: The prognosis of patients with type III tumors was poorer in comparison to that of type II tumors in adenocarcinoma of the esophagogastric junction (p<0.05). A significant difference was observed in the survival of patients with type III tumors between those with positive and negative lymph nodes (p<0.001). However, there was no such difference in patients with type II tumors. In a multivariate analysis, lymph node metastasis, age and the depth of tumor invasion were all found to be independent prognostic factors. Conclusions: The prognosis of patients with lymph node metastasis of type III adenocarcinoma of the esophagogastric junction was found to be extremely poor. An aggressive treatment after surgery may therefore be necessary to improve the survival of this population.

UR - http://www.scopus.com/inward/record.url?scp=41549091793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549091793&partnerID=8YFLogxK

M3 - Article

C2 - 18507087

AN - SCOPUS:41549091793

VL - 55

SP - 103

EP - 107

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 81

ER -